ATE369871T1 - Verfahren zur behandlung von hautkrebs mittels zusammensetzungen, die einen endothelinrezeptor-b-hemmer enthalten - Google Patents

Verfahren zur behandlung von hautkrebs mittels zusammensetzungen, die einen endothelinrezeptor-b-hemmer enthalten

Info

Publication number
ATE369871T1
ATE369871T1 AT00946969T AT00946969T ATE369871T1 AT E369871 T1 ATE369871 T1 AT E369871T1 AT 00946969 T AT00946969 T AT 00946969T AT 00946969 T AT00946969 T AT 00946969T AT E369871 T1 ATE369871 T1 AT E369871T1
Authority
AT
Austria
Prior art keywords
endothelin receptor
inhibitor
compositions containing
skin cancer
treating skin
Prior art date
Application number
AT00946969T
Other languages
English (en)
Inventor
Paul Patterson
Coutre-Lahav Ronit Le
Original Assignee
California Inst Of Techn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Inst Of Techn filed Critical California Inst Of Techn
Application granted granted Critical
Publication of ATE369871T1 publication Critical patent/ATE369871T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/5754—Endothelin, vasoactive intestinal contractor [VIC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00946969T 1999-06-29 2000-06-29 Verfahren zur behandlung von hautkrebs mittels zusammensetzungen, die einen endothelinrezeptor-b-hemmer enthalten ATE369871T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14145099P 1999-06-29 1999-06-29
US09/404,626 US6545048B1 (en) 1999-06-29 1999-09-23 Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity

Publications (1)

Publication Number Publication Date
ATE369871T1 true ATE369871T1 (de) 2007-09-15

Family

ID=26839135

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00946969T ATE369871T1 (de) 1999-06-29 2000-06-29 Verfahren zur behandlung von hautkrebs mittels zusammensetzungen, die einen endothelinrezeptor-b-hemmer enthalten

Country Status (11)

Country Link
US (1) US6545048B1 (de)
EP (1) EP1280552B1 (de)
AT (1) ATE369871T1 (de)
AU (1) AU6065000A (de)
CA (1) CA2376912A1 (de)
CY (1) CY1108778T1 (de)
DE (1) DE60036025T2 (de)
DK (1) DK1280552T3 (de)
ES (1) ES2292454T3 (de)
PT (1) PT1280552E (de)
WO (1) WO2001000198A2 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3050424B2 (ja) * 1991-07-12 2000-06-12 塩野義製薬株式会社 ヒトエンドセリンリセプター
US7566452B1 (en) * 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
TWI306760B (en) * 2000-08-07 2009-03-01 Abbott Lab Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same
AU2003222427B8 (en) * 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US20070286845A1 (en) * 2000-11-17 2007-12-13 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US8071740B2 (en) * 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20100282634A1 (en) * 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
US8039261B2 (en) * 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
AU2002250034A1 (en) * 2001-02-08 2002-08-19 Sequitur, Inc. Methods of light activated release 0f ligands from endosomes
WO2003006041A1 (fr) * 2001-07-12 2003-01-23 Takeda Chemical Industries, Ltd. Agents prophylactiques/therapeutiques contre les tumeurs malignes
CN100506284C (zh) * 2001-10-19 2009-07-01 脉管生物生长有限公司 多核苷酸构建体、药物组合物以及靶向的下调血管生成和抗癌的治疗方法
AU2002350115A1 (en) 2001-11-01 2003-05-12 Spectrum Pharmaceuticals, Inc. Medical compositions for intravesical treatment of bladder cancer
US8563592B2 (en) 2001-11-01 2013-10-22 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment and methods
ATE556714T1 (de) 2002-02-01 2012-05-15 Life Technologies Corp Doppelsträngige oligonukleotide
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
CA2502848C (en) 2002-10-24 2012-10-02 The Board Of Trustees Of The University Of Illinois Use of irl-1620 and paclitaxel for preventing and treating breast tumors
US8026216B2 (en) 2002-10-24 2011-09-27 Spectrum Pharmaceuticals, Inc. Methods and compositions for contributing to the treatment of cancers
US20070032422A1 (en) 2002-10-24 2007-02-08 Spectrum Pharmaceuticals, Inc. Methods, compositions and articles of manufacture for contributing to the treatment of cancers
US8217010B2 (en) 2002-10-24 2012-07-10 The Board Of Trustees Of The University Of Illinois Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors
EP1526380A1 (de) * 2003-10-21 2005-04-27 Progenika Biopharma, S.A. Verfahren zur in vitro Diagnose und in vitro Prognose von Pankreaskarzinom und für die Entwicklung von Arzneimittel gegen Pankreaskarzinom
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
EP1782072A2 (de) * 2004-04-15 2007-05-09 Reglia AB Materialien und verfahren zum screening von modulatoren neuraler regeneration
US20060094676A1 (en) * 2004-10-29 2006-05-04 Ronit Lahav Compositions and methods for treating cancer using compositions comprising an inhibitor of endothelin receptor activity
DE602006019733D1 (de) 2005-07-19 2011-03-03 Population Council Inc Verfahren und zusammensetzungen zur notfallbedingten verhütung mithilfe von endothelin-rezeptor-antagonisten
BRPI0722292A2 (pt) 2006-08-31 2014-04-15 Spectrum Pharmaceuticals Inc Sensibilização de células de tumor à terapia com radiação pela administração de agonistas de endotelina
US9289426B2 (en) * 2007-03-21 2016-03-22 University Of Pennsylvania Methods and compositions for treating solid tumors and enhancing tumor vaccines
WO2009033660A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of octreotide as a therapeutic agent
US20090205661A1 (en) * 2008-02-20 2009-08-20 Nellcor Puritan Bennett Llc Systems and methods for extended volume range ventilation
AU2010241564B2 (en) 2009-04-30 2014-07-31 Midwestern University Novel therapeutic treatments using centhaquin
MA34057B1 (fr) 2010-02-23 2013-03-05 Genentech Inc Compositions et methodes pour le diagnostic et le traitement d'une tumeur
US9308235B2 (en) 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
JP2015528818A (ja) 2012-08-02 2015-10-01 ジェネンテック， インコーポレイテッド 抗ｅｔｂｒ抗体およびイムノコンジュゲート
CA2879670A1 (en) 2012-08-02 2014-02-06 Genentech, Inc. Anti-etbr antibodies and immunoconjugates
WO2015006324A2 (en) * 2013-07-08 2015-01-15 Midwesterern University Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist
JP6903055B2 (ja) 2015-08-03 2021-07-14 イーエヌビー・セラピューティクス・インク Ｅｔｂｒ活性化に関連した癌を治療するための組成物及び方法
JP7539151B2 (ja) * 2018-01-12 2024-08-23 イーエヌビー・セラピューティクス・インク Ｅｔｂｒ活性化に関連する癌を処置するための重水素化化合物、組成物、および方法
WO2021011925A1 (en) * 2019-07-17 2021-01-21 Enb Therapeutics, Inc. Treatment of urothelial and kidney cancers by use of endothelin b receptor antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550110A (en) * 1992-04-22 1996-08-27 Warner-Lambert Company Endothelin Antagonists II
US6063911A (en) 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
US6030975A (en) 1997-03-14 2000-02-29 Basf Aktiengesellschaft Carboxylic acid derivatives, their preparation and use in treating cancer

Also Published As

Publication number Publication date
WO2001000198A3 (en) 2002-10-31
ES2292454T3 (es) 2008-03-16
CA2376912A1 (en) 2001-01-04
EP1280552A2 (de) 2003-02-05
EP1280552B1 (de) 2007-08-15
WO2001000198A2 (en) 2001-01-04
DK1280552T3 (da) 2008-01-07
DE60036025D1 (de) 2007-09-27
CY1108778T1 (el) 2014-04-09
DE60036025T2 (de) 2008-04-30
PT1280552E (pt) 2007-11-23
US6545048B1 (en) 2003-04-08
AU6065000A (en) 2001-01-31

Similar Documents

Publication Publication Date Title
ATE369871T1 (de) Verfahren zur behandlung von hautkrebs mittels zusammensetzungen, die einen endothelinrezeptor-b-hemmer enthalten
ATE334985T1 (de) Verbindungen, verfahren und pharmazeutische zubereitungen zur behandlung von zellschäden wie zum beispiel schäden an nerven- oder kerzgefässgewebe
DE69736745D1 (de) Verfahren zur behandlung von prostaterkrankungen unter verwendung von vitamin-d-formulierungen mit verzögerter und/oder verlängerter wirkstofffreigabe
ATE339957T1 (de) Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs
DE69733968D1 (de) Norbornen- und norbornandiolen zur behandlung von pigmentierungsstörungen, neurodegenerativen erkrankungen oder proliferativen hauterkrankungen
DE60312309D1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
SG169224A1 (en) Method for treatment of tumors using nordihydrogualaretic acid derivatives
ES2082198T3 (es) Inhibidores de esteroide-sulfatasa.
ATE345785T1 (de) Inhibitoren der proteasomalen aktivität zur stimulierung des haarwuchses
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
ATE350030T1 (de) Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
AR023400A1 (es) Metodos para inducir la muerte de celulas cancerosas y la regresion de tumores
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
ATE282425T1 (de) Verfahren zur behandlung von endothelialen verletzungen
ATE404202T1 (de) Die verwendung von potenten, selektiven und nontoxischen c-kithemmern zur behandlung von interstitieller blasenentzündung
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE602004022285D1 (de) Verfahren zur behandlung von erkrankungen mit hsp90-hemmenden mitteln in kombination mit antimitotika
NO20050450L (no) Kombinasjon av ZD6474, en inhibitor av vaskulaer endotelial vekst faktor reseptor, med radioterapi ved behandling av kreft
ATE500855T1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
DE69920205D1 (de) Verwendung von metall-proteinase-inhibitoren, um das wachstum der haare oder körperhaare zu induzieren und/oder zu stimulieren und/oder den haarausfall zu verlangsamen
DE69433685D1 (de) Unterdrückung von inhibitoren
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
ATE260282T1 (de) Aromatische ester von camptothecinen und verfahren zur behandlung von krebserkrankungen
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1280552

Country of ref document: EP